About SEQURNA

SEQURNA AB is a pioneering biotech startup spun out from Karolinska Institutet, specializing in synthetic thermostable RNase inhibitors for RNA-focused workflows. Our innovative technology simplifies RNA-sequencing and in situ sequencing processes, making them more accessible, cost-effective, and sustainable. Based in Stockholm and partnered with Nasdaq-Nordic-listed Genovis AB, SEQURNA is at the forefront of enabling next-generation RNA research and diagnostics worldwide.

SEQURNA management team

Board Member & Co-founder. CEO

Björn Reinius, PhD

Björn Reinius (PhD) is a chemist and Associate Professor at the Department of Medical Biochemistry and Biophysics at the Karolinska Institute. He and his academic laboratory is known for major discoveries in X-chromosome regulation and early groundbreaking work on RNA-extraction-free molecular assays for diagnostics of Covid-19, which has been applied in millions of clinical tests internationally. Björn is the CEO and a Co-founder of SEQURNA.

Board Member and Chairman. CEO Genovis

Fredrik Olsson, Civ Eng

Fredrik Olsson has broad experience of production processes from the biotechnology and food industry where a large part of his work involves establishing processes and quality systems for various industry-specific standards as well as a general system. Fredrik is the Chairman of the Board and CEO of Genovis.
Genovis is a biotech company listed on Nasdaq First North Growth Market specializing in the development of innovative enzyme-based tools in life science research and biopharmaceutical applications. Since summer 2024,Genovis owns 25% of shares in SEQURNA.

Board Member & Co-founder. R&D Molecular Assays

Joyce Noble, PhD

Joyce Carol Noble (PhD) is a molecular biologist with special expertise in RNA regulation and detection techniques. Joyce is the Lead Research & Development Specialist and is a Board Member and Co-founder of SEQURNA.

Co-founder. R&D Bioinformatics

Antonio Lentini, PhD

Antonio Lentini (PhD) is a bioinformatician with a wide expertise in sequencing-based methodologies and single-cell techniques. He is the Lead Computational Research & Development Specialist, and Co-founder of SEQURNA.

Board Member. Senior Scientific Advisor

Rickard Sandberg, PhD

Rickard Sandberg is Professor at the Department of Cell & Molecular Biology at the Karolinska Institute and a pioneer in the field of single-cell genomics. He and his academic laboratory is known for multiple breakthroughs in transcriptomics, including the development of widely used single-cell RNA-seq methods, such as Smart-seq, Smart-seq2, Smart-seq3, Small-seq, NASC-seq. Rickard is the Senior Scientific Advisor at SEQURNA.

R&D Molecular Assays

Michael Hagemann-Jensen, PhD

Michael Hagemann-Jensen (PhD) is a methods specialist in RNA biology and biotechnology. He is acclaimed for spearheading the development of multiple refined single-cell RNA-seq protocols, such as Smart-seq3, Smart-seq3xpress, and Small-seq. Michael is a Research & Development Specialist at SEQURNA

Funding and partnerships

KI Holding KI Innovations Genovis Vinnova